Interleukin-4 Therapeutic Vaccines for the Treatment of Human or Animal Immune-Related Diseases

A therapeutic vaccine and animal immunization technology, applied in allergic diseases, gene therapy, and vector-borne disease resistance, can solve problems such as increased costs, short antibody half-life, and easy allergic reactions

Active Publication Date: 2011-12-07
潍坊康奥思生物技术有限公司
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the short half-life of the antibody (the half-life of IgG is about 21-28 days), repeated injections are required, which not only increases the cost, but also easily causes allergic reactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Interleukin-4 Therapeutic Vaccines for the Treatment of Human or Animal Immune-Related Diseases
  • Interleukin-4 Therapeutic Vaccines for the Treatment of Human or Animal Immune-Related Diseases
  • Interleukin-4 Therapeutic Vaccines for the Treatment of Human or Animal Immune-Related Diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Example 1: Construction and vaccine preparation of mouse IL-4 gene recombinant vaccine

[0016] According to the whole gene coding sequence of mouse IL-4, a pair of suitable primers were designed to amplify IL-4 cDNA sequence by RT-PCR method. Then, after the DNA sequence was determined to prove that the amplified cDNA sequence was correct, it was cloned into the appropriate part of the pET-32 fusion expression vector, and the recombinant plasmid and the pET-32 fusion expression vector blank control plasmid were further transferred into Escherichia coli strains for proper expression were used for large-scale fermentation to extract and purify the IL-4 fusion protein and the thioredoxin expressed by the vector control. After mixing the purified IL-4 fusion protein or the thioredoxin expressed by the carrier control with oil adjuvant or aluminum gel adjuvant in an appropriate proportion [according to the content of the purified IL-4 fusion protein, for oil adjuvant vaccin...

Embodiment 2

[0019] Example 2: Safety test and allergic reaction test of mouse IL-4 gene recombinant vaccine

[0020] According to the method of Example 1, the purified IL-4 fusion protein or the thioredoxin expressed by the carrier control was properly diluted with physiological saline and then mixed with oil adjuvant or aluminum gel adjuvant at a volume ratio of 1:1 to prepare IL -4 fusion protein vaccine or vehicle control thioredoxin vaccine. The prepared IL-4 fusion protein vaccine was divided into three different dose groups of low (0.1ml, about 1 dose), medium (0.25ml, about 2.5 doses), high (0.5ml, about 5 doses) to immunize BALB respectively / c mice, pET-32 vector vaccine and normal saline control group were set up separately, 5 mice in each group, injected subcutaneously at multiple points. The second and third immunization injections were performed at intervals of 3 weeks. After the vaccine was injected, the mice were observed for adverse reactions, allergies, and death. The ...

Embodiment 3

[0021] Embodiment 3: The test of enhancing anti-tumor activity of mouse IL-4 gene recombinant vaccine

[0022] According to the method of Example 1, the purified IL-4 fusion protein or the thioredoxin expressed by the carrier control was properly diluted with physiological saline and then mixed with aluminum gel adjuvant at a ratio of 1:1 to prepare the experimental or control vaccine. It is required that the amount of IL-4 fusion protein or carrier control thioredoxin in each vaccine is about 15-20 μg; the volume of each vaccine is about 0.1 ml. The experimental mice were inoculated intraperitoneally (i.p.) with the IL-4 gene recombinant aluminum gel vaccine prepared in Example 1 3 weeks and 1 week before the tumor cell attack, respectively, and a pET-32 carrier aluminum gel vaccine and normal saline immunized control group were also set up . Tumor growth was checked every 3 days after tumor inoculation, and the experiment ended at 60 days. The results showed that the IL-4 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an interleukin-4 therapeutic vaccine for treating immune related diseases of humans or animals. The interleukin-4 therapeutic vaccine is a protein vaccine or coupling protein vaccine of any form prepared by taking the natural or artificially synthesized complete protein or protein fragment of interleukin-4 as an antigen; or the interleukin-4 therapeutic vaccine is a gene vaccine or fusion gene vaccine of any form prepared by taking the complete gene or gene fragment of interleukin-4 as the antigen gene or the major antigen gene. The IL (interleukin)-4 vaccine is used for performing active immunotherapy on a host, generally, the effective time lasts for about 2-3 months by immunization for the first time, the effective therapeutic time lasts for about half a year by secondary immunization, and recovery can be achieved by 1-3 times of immunotherapy. Compared with direct application of anti-IL-4 antibody for treatment, the invention has the characteristics of few times of application, low dose and the like, thereby greatly reducing the therapeutic cost, and also greatly reducing the possibility of generating allergic reaction.

Description

technical field [0001] The invention relates to an interleukin-4 therapeutic vaccine that can be used for treating human or animal immune-related diseases. Background technique [0002] So far, people still lack more effective treatment methods for chronic infectious diseases caused by intracellular parasitic pathogens (viruses, bacteria, parasites, etc.), and the preventive effect of vaccines is not satisfactory. Theoretically, such chronic infectious diseases require the host to produce a strong type (Th1) anti-infection immune response to eliminate pathogens, but how to induce the body to produce a strong Th1 anti-infection immune response is still a difficult problem. According to the applicant's long-term exploration and research, most of the clinical stages of such chronic infectious diseases show a strong second-type (Th2) anti-infection immune response, that is, the Th2 anti-infection immune response is the main one; while subclinical infection Most of them showed a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61K48/00A61P37/00
CPCY02A50/30
Inventor 刘永庆
Owner 潍坊康奥思生物技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap